Caribou Historical Income Statement

CRBU Stock

USD 2.19 0.01 0.45%

Historical analysis of Caribou Biosciences income statement accounts such as Net Interest Income of 119.7 K, Interest Income of 126.5 K or Depreciation And Amortization of 2.4 M can show how well Caribou Biosciences performed in making a profits. Evaluating Caribou Biosciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Caribou Biosciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Caribou Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Caribou Biosciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Caribou Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Caribou Stock please use our How to Invest in Caribou Biosciences guide.

About Caribou Income Statement Analysis

Caribou Biosciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Caribou Biosciences shareholders. The income statement also shows Caribou investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Caribou Biosciences Income Statement Chart

At this time, Caribou Biosciences' Tax Provision is comparatively stable compared to the past year. Interest Expense is likely to gain to about 10.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2.4 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Research Development

Total Revenue

Total revenue comprises all receipts Caribou Biosciences generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Caribou Biosciences. It is also known as Caribou Biosciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Caribou Biosciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Caribou Biosciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Caribou Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Caribou Stock please use our How to Invest in Caribou Biosciences guide.At this time, Caribou Biosciences' Tax Provision is comparatively stable compared to the past year. Interest Expense is likely to gain to about 10.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2.4 M in 2024.

	2020	2021	2023	2024 (projected)
Interest Income	236K	148K	133.2K	126.5K
Net Interest Income	216K	140K	126K	119.7K

Interest Income Net Interest Income

Caribou Biosciences income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Non Operating Income Net Other	Selling And Marketing Expenses
Tax Provision		-1.0	-1.0	0.38	0.75	0.8	0.77	-0.28	0.85	-0.87	-0.92	-0.87	0.86	-0.87	0.45	0.85	0.7	-0.89	0.51	-0.91	1.0	0.75	-0.56
Net Interest Income	-1.0		1.0	-0.35	-0.73	-0.76	-0.76	0.28	-0.82	0.84	0.89	0.84	-0.84	0.84	-0.45	-0.82	-0.69	0.86	-0.48	0.89	-1.0	-0.73	0.54
Interest Income	-1.0	1.0		-0.35	-0.73	-0.77	-0.76	0.28	-0.83	0.84	0.9	0.84	-0.84	0.85	-0.45	-0.83	-0.69	0.87	-0.48	0.89	-1.0	-0.73	0.55
Depreciation And Amortization	0.38	-0.35	-0.35		0.82	0.84	0.57	-0.37	0.78	-0.75	-0.67	-0.75	0.75	-0.74	0.44	0.78	0.76	-0.7	0.77	-0.67	0.38	0.82	-0.41
Interest Expense	0.75	-0.73	-0.73	0.82		0.91	0.91	-0.6	0.91	-0.96	-0.93	-0.96	0.9	-0.96	0.73	0.91	0.86	-0.95	0.92	-0.94	0.75	1.0	-0.79
Selling General Administrative	0.8	-0.76	-0.77	0.84	0.91		0.76	-0.34	0.98	-0.96	-0.95	-0.97	0.97	-0.97	0.48	0.98	0.87	-0.95	0.75	-0.94	0.8	0.91	-0.54
Total Revenue	0.77	-0.76	-0.76	0.57	0.91	0.76		-0.81	0.83	-0.88	-0.85	-0.88	0.84	-0.88	0.91	0.83	0.86	-0.88	0.9	-0.87	0.77	0.91	-0.92
Gross Profit	-0.28	0.28	0.28	-0.37	-0.6	-0.34	-0.81		-0.45	0.48	0.39	0.47	-0.48	0.47	-0.98	-0.45	-0.66	0.46	-0.82	0.44	-0.28	-0.61	0.85
Other Operating Expenses	0.85	-0.82	-0.83	0.78	0.91	0.98	0.83	-0.45		-0.96	-0.94	-0.96	1.0	-0.96	0.58	1.0	0.94	-0.95	0.76	-0.95	0.85	0.91	-0.59
Operating Income	-0.87	0.84	0.84	-0.75	-0.96	-0.96	-0.88	0.48	-0.96		0.99	1.0	-0.96	1.0	-0.63	-0.96	-0.87	1.0	-0.83	0.99	-0.87	-0.96	0.73
Net Income From Continuing Ops	-0.92	0.89	0.9	-0.67	-0.93	-0.95	-0.85	0.39	-0.94	0.99		0.99	-0.94	0.99	-0.56	-0.94	-0.8	1.0	-0.75	1.0	-0.92	-0.93	0.69
Ebit	-0.87	0.84	0.84	-0.75	-0.96	-0.97	-0.88	0.47	-0.96	1.0	0.99		-0.96	1.0	-0.62	-0.96	-0.86	1.0	-0.82	0.99	-0.87	-0.96	0.72
Research Development	0.86	-0.84	-0.84	0.75	0.9	0.97	0.84	-0.48	1.0	-0.96	-0.94	-0.96		-0.96	0.6	1.0	0.95	-0.94	0.76	-0.94	0.86	0.9	-0.6
Ebitda	-0.87	0.84	0.85	-0.74	-0.96	-0.97	-0.88	0.47	-0.96	1.0	0.99	1.0	-0.96		-0.62	-0.96	-0.86	1.0	-0.82	0.99	-0.87	-0.96	0.72
Cost Of Revenue	0.45	-0.45	-0.45	0.44	0.73	0.48	0.91	-0.98	0.58	-0.63	-0.56	-0.62	0.6	-0.62		0.58	0.74	-0.62	0.88	-0.6	0.45	0.73	-0.92
Total Operating Expenses	0.85	-0.82	-0.83	0.78	0.91	0.98	0.83	-0.45	1.0	-0.96	-0.94	-0.96	1.0	-0.96	0.58		0.94	-0.95	0.76	-0.95	0.85	0.91	-0.59
Reconciled Depreciation	0.7	-0.69	-0.69	0.76	0.86	0.87	0.86	-0.66	0.94	-0.87	-0.8	-0.86	0.95	-0.86	0.74	0.94		-0.83	0.82	-0.82	0.7	0.86	-0.63
Income Before Tax	-0.89	0.86	0.87	-0.7	-0.95	-0.95	-0.88	0.46	-0.95	1.0	1.0	1.0	-0.94	1.0	-0.62	-0.95	-0.83		-0.8	1.0	-0.89	-0.95	0.73
Total Other Income Expense Net	0.51	-0.48	-0.48	0.77	0.92	0.75	0.9	-0.82	0.76	-0.83	-0.75	-0.82	0.76	-0.82	0.88	0.76	0.82	-0.8		-0.78	0.51	0.92	-0.89
Net Income	-0.91	0.89	0.89	-0.67	-0.94	-0.94	-0.87	0.44	-0.95	0.99	1.0	0.99	-0.94	0.99	-0.6	-0.95	-0.82	1.0	-0.78		-0.91	-0.94	0.72
Income Tax Expense	1.0	-1.0	-1.0	0.38	0.75	0.8	0.77	-0.28	0.85	-0.87	-0.92	-0.87	0.86	-0.87	0.45	0.85	0.7	-0.89	0.51	-0.91		0.75	-0.56
Non Operating Income Net Other	0.75	-0.73	-0.73	0.82	1.0	0.91	0.91	-0.61	0.91	-0.96	-0.93	-0.96	0.9	-0.96	0.73	0.91	0.86	-0.95	0.92	-0.94	0.75		-0.79
Selling And Marketing Expenses	-0.56	0.54	0.55	-0.41	-0.79	-0.54	-0.92	0.85	-0.59	0.73	0.69	0.72	-0.6	0.72	-0.92	-0.59	-0.63	0.73	-0.89	0.72	-0.56	-0.79

Click cells to compare fundamentals

Caribou Biosciences Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Caribou Historical Income Statement

About Caribou Income Statement Analysis

Caribou Biosciences Income Statement Chart

Total Revenue

Other Operating Expenses

Caribou Biosciences income statement Correlations

Caribou Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Caribou Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Income Tax Expense	+ 1.0	Tax Provision
Interest Income	+ 1.0	Net Interest Income
Non Operating Income Net Other	+ 1.0	Interest Expense
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income

Income Tax Expense	- 1.0	Interest Income
Income Tax Expense	- 1.0	Net Interest Income
Interest Income	- 1.0	Tax Provision
Net Interest Income	- 1.0	Tax Provision
Cost Of Revenue	- 0.98	Gross Profit
Ebitda	- 0.97	Selling General Administrative